Carlos Grande
Madrid, MD 28029, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI.
Journal: ESMO open
Published: February 05, 2025
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.
Journal: Blood cancer journal
Published: March 26, 2024
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 17, 2024
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
Journal: British journal of haematology
Published: February 20, 2023
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Journal: International journal of hematology
Published: February 02, 2022
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Journal: Frontiers in immunology
Published: January 15, 2022
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.
Journal: Blood cancer journal
Published: August 23, 2021
Last Updated: 09/26/2026